Should O O O O
You O O O O
Get O O O O
the O O O O
New O O O O
RSV O O O O
Vaccine? O O O O
[Originally O O O O
published: O O O O
July O O O O
24, O O O O
2023. O O O O
Updated: O O O O
August O O O O
28, O O O O
2023] O O O O
This O O O O
winter, O O O O
when O O O O
the O O O O
usual O O O O
sneezing, O O O O
wheezing, O O O O
coughing, O O O O
and O O O O
fevers O O O O
start O O O O
up, O O O O
there O O O O
will O O O O
be O O O O
extra O O O O
protection O O O O
for O O O O
people O O O O
at O O O O
high O O O O
risk O O O O
from O O O O
at O O O O
least O O O O
one O O O O
common O O O O
illness. O O O O
[Respiratory O O O O
syncytial O O O O
virus O O O O
(RSV)](https://www.yalemedicine.org/conditions/rsv-respiratory-syncytial-virus) O O O O
causes O O O O
mild O O O O
cold O O O O
symptoms O O O O
in O O O O
most O O O O
people O O O O
but O O O O
can O O O O
lead O O O O
to O O O O
hospitalization O O O O
and O O O O
even O O O O
death O O O O
in O O O O
older O O O O
people O O O O
and O O O O
babies. O O O O
But O O O O
now, O O O O
two O O O O
new O O O O
RSV O O O O
vaccines O O O O
aimed O O O O
at O O O O
older O O O O
people O O O O
and O O O O
a O O O O
monoclonal O O O O
antibody O O O O
for O O O O
children O O O O
up O O O O
to O O O O
age O O O O
2 O O O O
could O O O O
become O O O O
available O O O O
as O O O O
soon O O O O
as O O O O
late O O O O
summer O O O O
or O O O O
early O O O O
fall. O O O O
"A O O O O
lot O O O O
is O O O O
changing O O O O
for O O O O
RSV," O O O O
says O O O O
[Scott O O O O
Roberts, O O O O
MD](https://www.yalemedicine.org/specialists/scott-c-roberts), O O O O
a O O O O
Yale O O O O
Medicine O O O O
infectious O O O O
diseases O O O O
specialist. O O O O
"There O O O O
have O O O O
been O O O O
attempts O O O O
to O O O O
make O O O O
a O O O O
vaccine O O O O
for O O O O
decades, O O O O
and O O O O
they O O O O
have O O O O
failed O O O O
for O O O O
a O O O O
variety O O O O
of O O O O
reasons." O O O O
One O O O O
turning O O O O
point O O O O
came O O O O
with O O O O
the O O O O
investigation O O O O
of O O O O
an O O O O
RSV O O O O
protein O O O O
called O O O O
"RSV O O O O
fusion O O O O
(F)" O O O O
that O O O O
provided O O O O
potent O O O O
stimulation O O O O
to O O O O
the O O O O
immune O O O O
system—research O O O O
that O O O O
paved O O O O
the O O O O
way O O O O
to O O O O
clinical O O O O
trials O O O O
showing O O O O
positive O O O O
results. O O O O
"Now, O O O O
it O O O O
looks O O O O
as O O O O
though O O O O
we O O O O
may O O O O
have O O O O
two O O O O
vaccines O O O O
for O O O O
adults O O O O
in O O O O
time O O O O
for O O O O
the O O O O
next O O O O
RSV O O O O
season—and O O O O
there O O O O
are O O O O
more O O O O
potential O O O O
RSV O O O O
therapeutics O O O O
in O O O O
the O O O O
pipeline," O O O O
Dr. O O O O
Roberts O O O O
says. O O O O
Older O O O O
people O O O O
start O O O O
to O O O O
lose O O O O
immunity O O O O
as O O O O
they O O O O
age—they're O O O O
unable O O O O
to O O O O
fight O O O O
off O O O O
infections, O O O O
such O O O O
as O O O O
RSV, O O O O
as O O O O
well O O O O
as O O O O
they O O O O
did O O O O
when O O O O
they O O O O
were O O O O
younger, O O O O
explains O O O O
Dr. O O O O
Roberts. O O O O
Plus, O O O O
the O O O O
[COVID-19](https://www.yalemedicine.org/conditions/covid-19) O O O O
pandemic O O O O
may O O O O
have O O O O
led O O O O
to O O O O
several O O O O
years O O O O
of O O O O
lost O O O O
immunity O O O O
since O O O O
RSV O O O O
wasn't O O O O
really O O O O
circulating O O O O
during O O O O
that O O O O
time. O O O O
However, O O O O
by O O O O
November O O O O
2022, O O O O
RSV O O O O
was O O O O
surging O O O O
in O O O O
children, O O O O
and O O O O
the O O O O
RSV O O O O
hospitalization O O O O
rate O O O O
for O O O O
older O O O O
adults O O O O
was O O O O
10 O O O O
times O O O O
higher O O O O
than O O O O
usual O O O O
for O O O O
that O O O O
time O O O O
of O O O O
year. O O O O
More O O O O
people O O O O
were O O O O
becoming O O O O
infected, O O O O
probably O O O O
as O O O O
a O O O O
result O O O O
of O O O O
more O O O O
in-person, O O O O
maskless O O O O
contact, O O O O
he O O O O
adds. O O O O
In O O O O
June, O O O O
the O O O O
[Centers O O O O
for O O O O
Disease O O O O
Control O O O O
and O O O O
Prevention O O O O
(CDC) O O O O
confirmed](https://www.cdc.gov/media/releases/2023/s0629-rsv.html) O O O O
the O O O O
Food O O O O
and O O O O
Drug O O O O
Administration O O O O
(FDA)'s O O O O
approval O O O O
of O O O O
the O O O O
two O O O O
vaccines O O O O
for O O O O
older O O O O
people, O O O O
specifying O O O O
that O O O O
those O O O O
ages O O O O
60 O O O O
and O O O O
older O O O O
"may" O O O O
get O O O O
them O O O O
based O O O O
on O O O O
"shared O O O O
clinical O O O O
decision-making," O O O O
meaning O O O O
they O O O O
may O O O O
receive O O O O
a O O O O
single O O O O
dose O O O O
based O O O O
on O O O O
discussions O O O O
with O O O O
their O O O O
health O O O O
care O O O O
provider O O O O
about O O O O
whether O O O O
RSV O O O O
vaccination O O O O
is O O O O
right O O O O
for O O O O
them. O O O O
This O O O O
summer, O O O O
the O O O O
FDA O O O O
also O O O O
approved O O O O
two O O O O
options O O O O
for O O O O
infants O O O O
and O O O O
toddlers. O O O O
The O O O O
CDC O O O O
signed O O O O
off O O O O
on O O O O
a O O O O
monoclonal O O O O
antibody O O O O
called O O O O
nirsevimab O O O O
(brand O O O O
name O O O O
Beyfortus) O O O O
for O O O O
all O O O O
infants O O O O
up O O O O
to O O O O
8 O O O O
months O O O O
old, O O O O
born O O O O
during—or O O O O
entering—their O O O O
first O O O O
RSV O O O O
season, O O O O
and O O O O
for O O O O
a O O O O
small O O O O
group O O O O
during O O O O
their O O O O
second O O O O
season O O O O
who O O O O
are O O O O
between O O O O
8 O O O O
and O O O O
19 O O O O
months O O O O
old O O O O
and O O O O
at O O O O
high O O O O
risk O O O O
for O O O O
severe O O O O
disease O O O O
(including O O O O
children O O O O
who O O O O
are O O O O
severely O O O O
immunocompromised). O O O O
The O O O O
FDA O O O O
also O O O O
approved O O O O
a O O O O
vaccine O O O O
for O O O O
pregnant O O O O
women O O O O
that O O O O
provides O O O O
them O O O O
with O O O O
antibodies O O O O
they O O O O
could O O O O
pass O O O O
along O O O O
to O O O O
the O O O O
fetus O O O O
and O O O O
protect O O O O
their O O O O
newborn O O O O
babies O O O O
from O O O O
birth O O O O
to O O O O
6 O O O O
months O O O O
of O O O O
age O O O O
from O O O O
severe O O O O
RSV. O O O O
That O O O O
vaccine O O O O
still O O O O
must O O O O
be O O O O
recommended O O O O
by O O O O
the O O O O
CDC, O O O O
and O O O O
it's O O O O
unclear O O O O
when O O O O
it O O O O
will O O O O
become O O O O
available. O O O O
Dr. O O O O
Roberts O O O O
and O O O O
[Thomas O O O O
Murray, O O O O
MD, O O O O
PhD](https://www.yalemedicine.org/specialists/thomas-s-murray), O O O O
a O O O O
Yale O O O O
Medicine O O O O
pediatric O O O O
infectious O O O O
diseases O O O O
specialist, O O O O
answered O O O O
questions O O O O
about O O O O
the O O O O
coming O O O O
options O O O O
for O O O O
older O O O O
adults O O O O
and O O O O
kids. O O O O
What Reason 4 O O
is Reason 4 O O
RSV, Reason 4 O O
and Reason 4 O O
why Reason 4 O O
is Reason 4 O O
it Reason 4 O O
a Reason 4 O O
threat Reason 4 O O
to Reason 4 O O
some Reason 4 O O
people? Reason 4 O O
RSV Reason 4 O O
is Reason 4 O O
a Reason 4 O O
common Reason 4 O O
respiratory Reason 4 O O
virus Reason 4 O O
that Reason 4 O O
usually Reason 4 O O
causes Reason 4 O O
mild, Reason 4 O O
cold-like Reason 4 O O
symptoms. Reason 4 O O
It's Reason 4 O O
a Reason 4 O O
seasonal Reason 4 O O
illness, Reason 4 O O
typically Reason 4 O O
starting Reason 4 O O
in Reason 4 O O
the Reason 4 O O
fall Reason 4 O O
and Reason 4 O O
peaking Reason 4 O O
in Reason 4 O O
the Reason 4 O O
winter. Reason 4 O O
Once Reason 4 O O
a Reason 4 O O
person Reason 4 O O
is Reason 4 O O
infected, Reason 4 O O
the Reason 4 O O
treatment Reason 4 O O
is Reason 4 O O
supportive Reason 4 O O
care, Reason 4 O O
such Reason 4 O O
as Reason 4 O O
over-the-counter Reason 4 O O
medications Reason 4 O O
and Reason 4 O O
maintaining Reason 4 O O
hydration. Reason 4 O O
Most Reason 4 O O
people Reason 4 O O
get Reason 4 O O
better Reason 4 O O
in Reason 4 O O
a Reason 4 O O
week Reason 4 O O
or Reason 4 O O
two. Reason 4 O O
But Reason 4 O O
when Reason 4 O O
RSV Reason 4 O O
makes Reason 4 O O
its Reason 4 O O
way Reason 4 O O
down Reason 4 O O
into Reason 4 O O
the Reason 4 O O
lungs, Reason 4 O O
causing Reason 4 O O
lower Reason 4 O O
respiratory Reason 4 O O
tract Reason 4 O O
disease Reason 4 O O
(LRTD), Reason 4 O O
it Reason 4 O O
can Reason 4 O O
cause Reason 4 O O
vulnerable Reason 4 O O
people, Reason 4 O O
including Reason 4 O O
[those Reason 4 O O
65 Reason 4 O O
and Reason 4 O O
older](https://www.cdc.gov/rsv/factsheet-older-adults.pdf), Reason 4 O O
to Reason 4 O O
develop Reason 4 O O
life-threatening Reason 4 O O
complications, Reason 4 O O
such Reason 4 O O
as Reason 4 O O
[pneumonia](https://www.yalemedicine.org/conditions/pneumonia), Reason 4 O O
and Reason 4 O O
make Reason 4 O O
existing Reason 4 O O
conditions, Reason 4 O O
such Reason 4 O O
as Reason 4 O O
[asthma](https://www.yalemedicine.org/conditions/asthma), Reason 4 O O
[congestive Reason 4 O O
heart Reason 4 O O
failure](https://www.yalemedicine.org/conditions/congestive-heart-failure), Reason 4 O O
and Reason 4 O O
[chronic Reason 4 O O
obstructive Reason 4 O O
pulmonary Reason 4 O O
disease Reason 4 O O
(COPD](https://www.yalemedicine.org/conditions/copd)), Reason 4 O O
worse. Reason 4 O O
Each Reason 4 O O
year, Reason 4 O O
this Reason 4 O O
leads Reason 4 O O
to Reason 4 O O
60,000 Reason 4 O O
and Reason 4 O O
160,000 Reason 4 O O
RSV Reason 4 O O
hospitalizations Reason 4 O O
in Reason 4 O O
adults Reason 4 O O
65 Reason 4 O O
and Reason 4 O O
older, Reason 4 O O
and Reason 4 O O
6,000 Reason 4 O O
to Reason 4 O O
10,000 Reason 4 O O
deaths. Reason 4 O O
Babies Reason 4 O O
are Reason 4 O O
susceptible Reason 4 O O
to Reason 4 O O
RSV Reason 4 O O
because Reason 4 O O
their Reason 4 O O
immune Reason 4 O O
systems Reason 4 O O
are Reason 4 O O
not Reason 4 O O
fully Reason 4 O O
formed, Reason 4 O O
adds Reason 4 O O
Dr. Reason 4 O O
Murray. Reason 4 O O
"Their Reason 4 O O
lungs Reason 4 O O
aren't Reason 4 O O
fully Reason 4 O O
developed. Reason 4 O O
So, Reason 4 O O
if Reason 4 O O
the Reason 4 O O
virus Reason 4 O O
gets Reason 4 O O
into Reason 4 O O
the Reason 4 O O
lungs Reason 4 O O
of Reason 4 O O
really Reason 4 O O
young Reason 4 O O
babies, Reason 4 O O
they Reason 4 O O
can Reason 4 O O
develop Reason 4 O O
respiratory Reason 4 O O
problems Reason 4 O O
and Reason 4 O O
need Reason 4 O O
support, Reason 4 O O
such Reason 4 O O
as Reason 4 O O
supplemental Reason 4 O O
oxygen, Reason 4 O O
to Reason 4 O O
help Reason 4 O O
them Reason 4 O O
breathe." Reason 4 O O
In Reason 4 O O
children Reason 4 O O
younger Reason 4 O O
than Reason 4 O O
5, Reason 4 O O
there Reason 4 O O
are Reason 4 O O
approximately Reason 4 O O
2.1 Reason 4 O O
million Reason 4 O O
RSV-related Reason 4 O O
outpatient Reason 4 O O
visits Reason 4 O O
a Reason 4 O O
year, Reason 4 O O
58,000 Reason 4 O O
to Reason 4 O O
80,000 Reason 4 O O
hospitalizations, Reason 4 O O
and Reason 4 O O
100 Reason 4 O O
to Reason 4 O O
300 Reason 4 O O
deaths. Reason 4 O O
How O O O O
effective O O O O
are O O O O
the O O O O
RSV O O O O
vaccines O O O O
for O O O O
older O O O O
adults? O O O O
Both O O O O
vaccines O O O O
for O O O O
older O O O O
adults O O O O
use O O O O
traditional O O O O
platforms—similar O O O O
to O O O O
a O O O O
flu O O O O
shot O O O O
(and O O O O
not O O O O
to O O O O
be O O O O
confused O O O O
with O O O O
the O O O O
mRNA O O O O
technology O O O O
introduced O O O O
by O O O O
Pfizer-BioNTech O O O O
and O O O O
Moderna O O O O
to O O O O
prevent O O O O
COVID-19). O O O O
The O O O O
RSV O O O O
vaccines O O O O
work O O O O
by O O O O
introducing O O O O
an O O O O
inactivated O O O O
RSV O O O O
protein O O O O
into O O O O
the O O O O
body, O O O O
where O O O O
it O O O O
fuses O O O O
to O O O O
host O O O O
cells O O O O
and O O O O
stimulates O O O O
the O O O O
immune O O O O
system O O O O
to O O O O
recognize O O O O
the O O O O
actual O O O O
RSV O O O O
virus O O O O
if/when O O O O
it O O O O
encounters O O O O
it O O O O
and O O O O
help O O O O
prevent O O O O
severe O O O O
disease. O O O O
[Both O O O O
vaccines O O O O
performed O O O O
well O O O O
in O O O O
clinical O O O O
trials](https://www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm), O O O O
according O O O O
to O O O O
data O O O O
presented O O O O
to O O O O
the O O O O
FDA. O O O O
Arexvy, O O O O
developed O O O O
by O O O O
GSK, O O O O
was O O O O
the O O O O
first O O O O
to O O O O
receive O O O O
FDA O O O O
approval—in O O O O
early O O O O
May—based O O O O
on O O O O
data O O O O
from O O O O
a O O O O
trial O O O O
conducted O O O O
by O O O O
the O O O O
company O O O O
in O O O O
the O O O O
U.S. O O O O
and O O O O
internationally. O O O O
The O O O O
ongoing O O O O
trial O O O O
is O O O O
following O O O O
participants O O O O
through O O O O
three O O O O
RSV O O O O
seasons. O O O O
In O O O O
late O O O O
June, O O O O
GSK O O O O
reported O O O O
an O O O O
overall O O O O
efficacy O O O O
of O O O O
82.6% O O O O
against O O O O
lower O O O O
respiratory O O O O
tract O O O O
disease O O O O
during O O O O
the O O O O
first O O O O
season, O O O O
77.3% O O O O
for O O O O
mid-season, O O O O
and O O O O
67.2% O O O O
over O O O O
two O O O O
seasons. O O O O
Against O O O O
severe O O O O
disease, O O O O
efficacy O O O O
was O O O O
94.1% O O O O
during O O O O
the O O O O
first O O O O
season, O O O O
84.6% O O O O
at O O O O
mid-season, O O O O
and O O O O
78.8% O O O O
over O O O O
two O O O O
seasons. O O O O
The O O O O
second O O O O
vaccine, O O O O
called O O O O
Abrysvo, O O O O
from O O O O
Pfizer, O O O O
[showed O O O O
an O O O O
efficacy](https://www.nejm.org/doi/full/10.1056/NEJMoa2213836?query=featured_home) O O O O
of O O O O
almost O O O O
89% O O O O
against O O O O
LRTD O O O O
involving O O O O
at O O O O
least O O O O
three O O O O
symptoms O O O O
in O O O O
the O O O O
first O O O O
year O O O O
after O O O O
vaccination, O O O O
and O O O O
78.6% O O O O
mid-way O O O O
through O O O O
a O O O O
second O O O O
season O O O O
in O O O O
the O O O O
data O O O O
presented O O O O
to O O O O
the O O O O
FDA. O O O O
LRTD O O O O
symptoms O O O O
include O O O O
new O O O O
or O O O O
increased O O O O
cough, O O O O
wheezing, O O O O
sputum O O O O
(phlegm) O O O O
production, O O O O
shortness O O O O
of O O O O
breath, O O O O
and/or O O O O
tachypnea O O O O
(abnormally O O O O
rapid O O O O
breathing). O O O O
While O O O O
data O O O O
showed O O O O
that O O O O
one O O O O
vaccination O O O O
could O O O O
be O O O O
protective O O O O
for O O O O
at O O O O
least O O O O
two O O O O
seasons, O O O O
no O O O O
determination O O O O
has O O O O
been O O O O
made O O O O
on O O O O
how O O O O
frequently O O O O
the O O O O
shots O O O O
should O O O O
be O O O O
given. O O O O
Will O O O O
there O O O O
be O O O O
an O O O O
RSV O O O O
vaccine O O O O
available O O O O
for O O O O
children? O O O O
Abrysvo Reason 4 O O
(the Reason 4 O O
same Reason 4 O O
vaccine Reason 4 O O
recommended Reason 4 O O
for Reason 4 O O
older Reason 4 O O
people) Reason 4 O O
was Reason 4 O O
FDA-approved Reason 4 O O
in Reason 4 O O
August Reason 4 O O
for Reason 4 O O
pregnant Reason 4 O O
women, Reason 4 O O
who Reason 4 O O
would Reason 4 O O
pass Reason 4 O O
the Reason 4 O O
antibodies Reason 4 O O
on Reason 4 O O
to Reason 4 O O
their Reason 4 O O
fetuses Reason 4 O O
and Reason 4 O O
protect Reason 4 O O
their Reason 4 O O
newborns Reason 4 O O
for Reason 4 O O
up Reason 4 O O
to Reason 4 O O
6 Reason 4 O O
months. Reason 4 O O
Once Reason 4 O O
approval Reason 4 O O
is Reason 4 O O
finalized Reason 4 O O
by Reason 4 O O
the Reason 4 O O
CDC, Reason 4 O O
the Reason 4 O O
vaccine Reason 4 O O
will Reason 4 O O
be Reason 4 O O
given Reason 4 O O
to Reason 4 O O
mothers-to-be Reason 4 O O
at Reason 4 O O
32 Reason 4 O O
through Reason 4 O O
36 Reason 4 O O
weeks Reason 4 O O
gestational Reason 4 O O
age Reason 4 O O
of Reason 4 O O
pregnancy Reason 4 O O
in Reason 4 O O
a Reason 4 O O
single Reason 4 O O
injection. Reason 4 O O
Clinical Reason 4 O O
trials Reason 4 O O
for Reason 4 O O
the Reason 4 O O
vaccine Reason 4 O O
in Reason 4 O O
this Reason 4 O O
age Reason 4 O O
group Reason 4 O O
showed Reason 4 O O
an Reason 4 O O
81.8% Reason 4 O O
efficacy Reason 4 O O
in Reason 4 O O
preventing Reason 4 O O
severe Reason 4 O O
respiratory Reason 4 O O
illness Reason 4 O O
within Reason 4 O O
three Reason 4 O O
months Reason 4 O O
after Reason 4 O O
birth Reason 4 O O
and Reason 4 O O
69.4% Reason 4 O O
in Reason 4 O O
the Reason 4 O O
first Reason 4 O O
six Reason 4 O O
months Reason 4 O O
of Reason 4 O O
life. Reason 4 O O
However, Reason 4 O O
a Reason 4 O O
few Reason 4 O O
of Reason 4 O O
the Reason 4 O O
[FDA Reason 4 O O
advisors Reason 4 O O
expressed Reason 4 O O
concern](https://www.nytimes.com/2023/05/18/health/rsv-vaccine-infants-fda.html) Reason 4 O O
over Reason 4 O O
a Reason 4 O O
slight Reason 4 O O
increase Reason 4 O O
in Reason 4 O O
preterm Reason 4 O O
births Reason 4 O O
among Reason 4 O O
women Reason 4 O O
who Reason 4 O O
got Reason 4 O O
the Reason 4 O O
shot—5.6% Reason 4 O O
in Reason 4 O O
vaccinated Reason 4 O O
women Reason 4 O O
compared Reason 4 O O
to Reason 4 O O
4.7% Reason 4 O O
in Reason 4 O O
an Reason 4 O O
unvaccinated Reason 4 O O
group. Reason 4 O O
(FDA Reason 4 O O
officials Reason 4 O O
said Reason 4 O O
the Reason 4 O O
difference Reason 4 O O
was Reason 4 O O
not Reason 4 O O
statistically Reason 4 O O
significant.) Reason 4 O O
What O O O O
do O O O O
we O O O O
know O O O O
about O O O O
nirsevimab, O O O O
the O O O O
FDA-approved O O O O
monoclonal O O O O
antibody O O O O
for O O O O
infants O O O O
and O O O O
toddlers? O O O O
Nirsevimab, O O O O
which O O O O
was O O O O
developed O O O O
by O O O O
Sanofi O O O O
and O O O O
AstraZeneca, O O O O
is O O O O
given O O O O
in O O O O
a O O O O
single O O O O
injection O O O O
to O O O O
the O O O O
thigh. O O O O
A O O O O
Phase O O O O
3 O O O O
clinical O O O O
trial O O O O
showed O O O O
that O O O O
nirsevimab O O O O
reduced O O O O
RSV-triggered O O O O
lower O O O O
respiratory O O O O
tract O O O O
infections O O O O
serious O O O O
enough O O O O
to O O O O
require O O O O
medical O O O O
care O O O O
by O O O O
76.4% O O O O
and O O O O
cut O O O O
RSV O O O O
hospitalizations O O O O
in O O O O
healthy O O O O
full-term O O O O
and O O O O
near-full-term O O O O
infants O O O O
by O O O O
76.8%. O O O O
The O O O O
monoclonal O O O O
antibody O O O O
works O O O O
differently O O O O
than O O O O
a O O O O
vaccine. O O O O
"When O O O O
you're O O O O
injected O O O O
with O O O O
a O O O O
vaccine, O O O O
it O O O O
causes O O O O
your O O O O
body O O O O
to O O O O
produce O O O O
antibodies O O O O
to O O O O
protect O O O O
you O O O O
against O O O O
whatever O O O O
the O O O O
vaccine O O O O
is O O O O
for," O O O O
Dr. O O O O
Murray O O O O
says. O O O O
"The O O O O
monoclonal O O O O
antibody O O O O
bypasses O O O O
that O O O O
step. O O O O
Your O O O O
body O O O O
gets—in O O O O
this O O O O
case—a O O O O
single O O O O
kind O O O O
of O O O O
antibody O O O O
directly O O O O
injected O O O O
into O O O O
the O O O O
bloodstream O O O O
so O O O O
that O O O O
if O O O O
you're O O O O
infected O O O O
with O O O O
that O O O O
organism, O O O O
the O O O O
antibodies O O O O
will O O O O
bind O O O O
to O O O O
it O O O O
and O O O O
help O O O O
you O O O O
clear O O O O
the O O O O
infection." O O O O
The O O O O
antibody O O O O
reduces O O O O
hospitalization O O O O
significantly, O O O O
he O O O O
adds. O O O O
"Even O O O O
if O O O O
it O O O O
doesn't O O O O
completely O O O O
prevent O O O O
disease, O O O O
it O O O O
can O O O O
significantly O O O O
reduce O O O O
disease O O O O
severity. O O O O
This O O O O
will O O O O
be O O O O
extremely O O O O
helpful O O O O
this O O O O
year, O O O O
especially O O O O
after O O O O
the O O O O
RSV O O O O
surge O O O O
we O O O O
had O O O O
last O O O O
winter," O O O O
he O O O O
says. O O O O
"And O O O O
in O O O O
the O O O O
trials, O O O O
there O O O O
was O O O O
no O O O O
difference O O O O
in O O O O
adverse O O O O
effects O O O O
between O O O O
the O O O O
placebo O O O O
and O O O O
antibody O O O O
groups." O O O O
What O O O O
if O O O O
you O O O O
are O O O O
not O O O O
an O O O O
older O O O O
person O O O O
or O O O O
an O O O O
infant? O O O O
If Reason 3 O O
you Reason 3 O O
don't Reason 3 O O
fall Reason 3 O O
into Reason 3 O O
one Reason 3 O O
of Reason 3 O O
those Reason 3 O O
categories Reason 3 O O
and Reason 3 O O
are Reason 3 O O
otherwise Reason 3 O O
healthy, Reason 3 O O
you Reason 3 O O
probably Reason 3 O O
don't Reason 3 O O
need Reason 3 O O
a Reason 3 O O
preventive Reason 3 O O
therapy, Reason 3 O O
Dr. Reason 3 O O
Murray Reason 3 O O
explains. Reason 3 O O
"Virtually Reason 3 O O
every Reason 3 O O
child Reason 3 O O
has Reason 3 O O
experienced Reason 3 O O
RSV Reason 3 O O
by Reason 3 O O
the Reason 3 O O
age Reason 3 O O
of Reason 3 O O
2 Reason 3 O O
and Reason 3 O O
has Reason 3 O O
immunity," Reason 3 O O
he Reason 3 O O
says. Reason 3 O O
Older Reason 3 O O
children, Reason 3 O O
teenagers, Reason 3 O O
and Reason 3 O O
most Reason 3 O O
adults Reason 3 O O
have Reason 3 O O
strong Reason 3 O O
immunity Reason 3 O O
from Reason 3 O O
multiple Reason 3 O O
exposures Reason 3 O O
and Reason 3 O O
rarely Reason 3 O O
experience Reason 3 O O
LRTD Reason 3 O O
from Reason 3 O O
RSV. Reason 3 O O
"We Reason 3 O O
want Reason 3 O O
to Reason 3 O O
make Reason 3 O O
things Reason 3 O O
available Reason 3 O O
to Reason 3 O O
the Reason 3 O O
highest-risk Reason 3 O O
patients Reason 3 O O
first," Reason 3 O O
Dr. Reason 3 O O
Murray Reason 3 O O
says. Reason 3 O O
"We'll Reason 3 O O
have Reason 3 O O
to Reason 3 O O
wait Reason 3 O O
and Reason 3 O O
see Reason 3 O O
whether Reason 3 O O
or Reason 3 O O
not Reason 3 O O
the Reason 3 O O
vaccines Reason 3 O O
will Reason 3 O O
be Reason 3 O O
approved Reason 3 O O
for Reason 3 O O
people Reason 3 O O
at Reason 3 O O
other Reason 3 O O
ages Reason 3 O O
with Reason 3 O O
chronic Reason 3 O O
underlying Reason 3 O O
illnesses, Reason 3 O O
such Reason 3 O O
as Reason 3 O O
serious Reason 3 O O
heart Reason 3 O O
or Reason 3 O O
lung Reason 3 O O
problems." Reason 3 O O
Are O O O O
there O O O O
side O O O O
effects O O O O
from O O O O
the O O O O
vaccines O O O O
or O O O O
other O O O O
concerns? O O O O
The Reason 5 O O
CDC Reason 5 O O
advisory Reason 5 O O
panel Reason 5 O O
expressed Reason 5 O O
concerns Reason 5 O O
about Reason 5 O O
the Reason 5 O O
clinical Reason 5 O O
trial Reason 5 O O
data Reason 5 O O
to Reason 5 O O
the Reason 5 O O
point Reason 5 O O
where Reason 5 O O
they Reason 5 O O
changed Reason 5 O O
an Reason 5 O O
initially Reason 5 O O
strong Reason 5 O O
recommendation Reason 5 O O
to Reason 5 O O
get Reason 5 O O
the Reason 5 O O
vaccine, Reason 5 O O
if Reason 5 O O
eligible, Reason 5 O O
to Reason 5 O O
one Reason 5 O O
that Reason 5 O O
says Reason 5 O O
people Reason 5 O O
over Reason 5 O O
60 Reason 5 O O
"may" Reason 5 O O
get Reason 5 O O
an Reason 5 O O
RSV Reason 5 O O
vaccine Reason 5 O O
based Reason 5 O O
on Reason 5 O O
a Reason 5 O O
shared Reason 5 O O
discussion Reason 5 O O
with Reason 5 O O
their Reason 5 O O
doctors. Reason 5 O O
For Reason 5 O O
some, Reason 5 O O
this Reason 5 O O
may Reason 5 O O
mean Reason 5 O O
a Reason 5 O O
discussion Reason 5 O O
with Reason 5 O O
their Reason 5 O O
pharmacist. Reason 5 O O
(The Reason 5 O O
RSV Reason 5 O O
vaccines Reason 5 O O
will Reason 5 O O
be Reason 5 O O
covered Reason 5 O O
by Reason 5 O O
Medicare Reason 5 O O
Part Reason 5 O O
D Reason 5 O O
and, Reason 5 O O
thus, Reason 5 O O
will Reason 5 O O
be Reason 5 O O
administered Reason 5 O O
in Reason 5 O O
pharmacies Reason 5 O O
in Reason 5 O O
many Reason 5 O O
cases.) Reason 5 O O
One Reason 5 O O
issue Reason 5 O O
was Reason 5 O O
that Reason 5 O O
a Reason 5 O O
few Reason 5 O O
people Reason 5 O O
in Reason 5 O O
the Reason 5 O O
trials Reason 5 O O
developed Reason 5 O O
[Guillain-Barré Reason 5 O O
syndrome](https://www.yalemedicine.org/conditions/guillain-barre-syndrome) Reason 5 O O
in Reason 5 O O
the Reason 5 O O
days Reason 5 O O
following Reason 5 O O
the Reason 5 O O
shot. Reason 5 O O
Guillain-Barré Reason 5 O O
is Reason 5 O O
a Reason 5 O O
rare Reason 5 O O
disorder Reason 5 O O
that Reason 5 O O
causes Reason 5 O O
muscle Reason 5 O O
weakness Reason 5 O O
and Reason 5 O O
sometimes Reason 5 O O
paralysis. Reason 5 O O
In Reason 5 O O
addition, Reason 5 O O
[atrial Reason 5 O O
fibrillation](https://www.yalemedicine.org/conditions/atrial-fibrillation) Reason 5 O O
(an Reason 5 O O
arrhythmia Reason 5 O O
that Reason 5 O O
can Reason 5 O O
lead Reason 5 O O
to Reason 5 O O
blood Reason 5 O O
clots Reason 5 O O
in Reason 5 O O
the Reason 5 O O
heart) Reason 5 O O
within Reason 5 O O
30 Reason 5 O O
days Reason 5 O O
of Reason 5 O O
vaccination Reason 5 O O
was Reason 5 O O
reported Reason 5 O O
in Reason 5 O O
10 Reason 5 O O
participants Reason 5 O O
who Reason 5 O O
received Reason 5 O O
Arexvy Reason 5 O O
and Reason 5 O O
four Reason 5 O O
participants Reason 5 O O
who Reason 5 O O
received Reason 5 O O
a Reason 5 O O
placebo. Reason 5 O O
"One Reason 5 O O
could Reason 5 O O
argue Reason 5 O O
that Reason 5 O O
the Reason 5 O O
benefits Reason 5 O O
of Reason 5 O O
these Reason 5 O O
vaccines Reason 5 O O
far Reason 5 O O
outweigh Reason 5 O O
the Reason 5 O O
risks; Reason 5 O O
for Reason 5 O O
instance, Reason 5 O O
the Reason 5 O O
protection Reason 5 O O
afforded Reason 5 O O
against Reason 5 O O
severe Reason 5 O O
RSV Reason 5 O O
disease Reason 5 O O
is Reason 5 O O
greater Reason 5 O O
than Reason 5 O O
the Reason 5 O O
small Reason 5 O O
risk Reason 5 O O
of Reason 5 O O
Guillain-Barré Reason 5 O O
in Reason 5 O O
this Reason 5 O O
situation," Reason 5 O O
says Reason 5 O O
Dr. Reason 5 O O
Roberts. Reason 5 O O
There Reason 5 O O
will Reason 5 O O
be Reason 5 O O
continued Reason 5 O O
monitoring Reason 5 O O
for Reason 5 O O
Guillain-Barré Reason 5 O O
and Reason 5 O O
other Reason 5 O O
issues Reason 5 O O
once Reason 5 O O
the Reason 5 O O
RSV Reason 5 O O
vaccines Reason 5 O O
become Reason 5 O O
available, Reason 5 O O
he Reason 5 O O
adds. Reason 5 O O
Another O O O O
issue O O O O
was O O O O
that O O O O
most O O O O
of O O O O
the O O O O
participants O O O O
in O O O O
the O O O O
clinical O O O O
trials O O O O
were O O O O
in O O O O
their O O O O
60s, O O O O
so O O O O
there O O O O
was O O O O
little O O O O
data O O O O
on O O O O
other O O O O
high-risk O O O O
groups, O O O O
such O O O O
as O O O O
those O O O O
over O O O O
age O O O O
80. O O O O
Should O O O O
you O O O O
get O O O O
the O O O O
RSV O O O O
vaccine O O O O
if O O O O
you're O O O O
eligible? O O O O
Both Reason 5 O O
doctors Reason 5 O O
say Reason 5 O O
the Reason 5 O O
benefits Reason 5 O O
of Reason 5 O O
the Reason 5 O O
new Reason 5 O O
vaccines Reason 5 O O
for Reason 5 O O
older Reason 5 O O
adults Reason 5 O O
outweigh Reason 5 O O
the Reason 5 O O
potential Reason 5 O O
harms Reason 5 O O
in Reason 5 O O
cases Reason 5 O O
where Reason 5 O O
RSV Reason 5 O O
could Reason 5 O O
be Reason 5 O O
life-threatening. Reason 5 O O
They Reason 5 O O
recommend Reason 5 O O
them Reason 5 O O
to Reason 5 O O
all Reason 5 O O
eligible Reason 5 O O
older Reason 5 O O
adults, Reason 5 O O
particularly Reason 5 O O
those Reason 5 O O
with Reason 5 O O
underlying Reason 5 O O
health Reason 5 O O
conditions, Reason 5 O O
such Reason 5 O O
as Reason 5 O O
heart Reason 5 O O
or Reason 5 O O
lung Reason 5 O O
disease, Reason 5 O O
or Reason 5 O O
weakened Reason 5 O O
immune Reason 5 O O
systems. Reason 5 O O
They Reason 5 O O
also Reason 5 O O
suggest Reason 5 O O
that Reason 5 O O
people Reason 5 O O
who Reason 5 O O
are Reason 5 O O
vulnerable Reason 5 O O
or Reason 5 O O
could Reason 5 O O
infect Reason 5 O O
others Reason 5 O O
who Reason 5 O O
are Reason 5 O O
at Reason 5 O O
high Reason 5 O O
risk Reason 5 O O
take Reason 5 O O
additional Reason 5 O O
precautions Reason 5 O O
this Reason 5 O O
fall. Reason 5 O O
Since Reason 5 O O
RSV Reason 5 O O
is Reason 5 O O
spread Reason 5 O O
through Reason 5 O O
contact Reason 5 O O
with Reason 5 O O
contaminated Reason 5 O O
surfaces, Reason 5 O O
that Reason 5 O O
includes Reason 5 O O
[washing Reason 5 O O
hands](https://www.yalemedicine.org/news/how-to-wash-your-hands) Reason 5 O O
often, Reason 5 O O
keeping Reason 5 O O
hands Reason 5 O O
away Reason 5 O O
from Reason 5 O O
your Reason 5 O O
face, Reason 5 O O
avoiding Reason 5 O O
kissing Reason 5 O O
and Reason 5 O O
other Reason 5 O O
close Reason 5 O O
contact Reason 5 O O
with Reason 5 O O
people Reason 5 O O
who Reason 5 O O
have Reason 5 O O
cold-like Reason 5 O O
symptoms, Reason 5 O O
cleaning Reason 5 O O
frequently Reason 5 O O
touched Reason 5 O O
surfaces, Reason 5 O O
such Reason 5 O O
as Reason 5 O O
doorknobs Reason 5 O O
and Reason 5 O O
mobile Reason 5 O O
devices, Reason 5 O O
and Reason 5 O O
staying Reason 5 O O
home Reason 5 O O
when Reason 5 O O
you Reason 5 O O
are Reason 5 O O
sick. Reason 5 O O
"All Reason 5 O O
of Reason 5 O O
these Reason 5 O O
things Reason 5 O O
will Reason 5 O O
protect Reason 5 O O
against Reason 5 O O
RSV," Reason 5 O O
Dr. Reason 5 O O
Roberts Reason 5 O O
says. Reason 5 O O
Should Reason 5 O O
you Reason 5 O O
get Reason 5 O O
a Reason 5 O O
COVID Reason 5 O O
booster, Reason 5 O O
flu Reason 5 O O
vaccine, Reason 5 O O
and Reason 5 O O
RSV Reason 5 O O
vaccine Reason 5 O O
all Reason 5 O O
at Reason 5 O O
once, Reason 5 O O
if Reason 5 O O
you Reason 5 O O
are Reason 5 O O
eligible? Reason 5 O O
That's Reason 5 O O
a Reason 5 O O
question Reason 5 O O
experts Reason 5 O O
are Reason 5 O O
still Reason 5 O O
working Reason 5 O O
to Reason 5 O O
answer—so Reason 5 O O
far Reason 5 O O
the Reason 5 O O
data Reason 5 O O
is Reason 5 O O
still Reason 5 O O
limited. Reason 5 O O
But Reason 5 O O
the Reason 5 O O
FDA Reason 5 O O
and Reason 5 O O
CDC Reason 5 O O
will Reason 5 O O
continue Reason 5 O O
to Reason 5 O O
monitor Reason 5 O O
the Reason 5 O O
vaccines. Reason 5 O O
According Reason 5 O O
to Reason 5 O O
the Reason 5 O O
[New Reason 5 O O
York Reason 5 O O
Times](https://www.nytimes.com/article/flu-covid-rsv-vaccines.html), Reason 5 O O
the Reason 5 O O
CDC Reason 5 O O
is Reason 5 O O
expected Reason 5 O O
to Reason 5 O O
make Reason 5 O O
recommendations Reason 5 O O
on Reason 5 O O
administration Reason 5 O O
of Reason 5 O O
the Reason 5 O O
three Reason 5 O O
vaccines Reason 5 O O
together Reason 5 O O
in Reason 5 O O
the Reason 5 O O
coming Reason 5 O O
weeks Reason 5 O O
